Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06205121 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis

A Phase 2 study of Pulmonary Sarcoidosis, sponsored by Molecure S.A..

Recruiting
Registry status
Phase 2
Development phase
96
Enrollment target
20
Study locations

NCT06205121: Recruiting Phase 2 study of Pulmonary Sarcoidosis, sponsored by Molecure S.A..

NCT06205121 is a Phase 2 study of Pulmonary Sarcoidosis that is actively recruiting participants, run by Molecure S.A.. The registered enrollment target is 96 participants, below the 796-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06205121, a Phase 2 study of Pulmonary Sarcoidosis, is actively recruiting participants, sponsored by Molecure S.A..

RECRUITING
Registry status
Phase 2
Development phase
96 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.

Primary Outcome

Response classed as Complete response, Partial response, Stable disease and Progressive disease based on Standard Uptake Volume (SUV) changes in the uptake for {18F\]FDG-PET/CT above the background (pulmonary parenchyma /ascending aorta) in pulmonary target lesions and any new lesions.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG OATD-01

Study Locations (20)

Other

  • Molecure Investigative Site - Vejle
  • Molecure Investigative Site - Bobigny
  • Molecure Investigative Site - Montpellier
  • Molecure Investigative Site - Paris
  • Molecure Investigative Site - Paris
  • Molecure Investigative Site - Essen
  • Molecure Investigative Site - Freiburg im Breisgau
  • Molecure Investigative Site - Mainz-GE
  • Molecure Investigative Site - Corfu
  • Molecure Investigative Site - Heraklion
  • Molecure Investigative Site - Pátrai
  • Molecure Investigative Site - Thessaloniki
  • Molecure Investigative Site - Nieuwegein

Alabama

  • Molecure Investigative Site - Birmingham

Kansas

  • Molecure Investigative Site - Kansas City

Maryland

  • Molecure Investigative Site - Baltimore

Minnesota

  • Molecure Investigative Site - Rochester

Ohio

  • Molecure Investigative Site - Cleveland

Pennsylvania

  • Molecure Investigative Site - Philadelphia

South Carolina

  • Molecure Investigative Site - Charleston

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2024-03-21
Est. Completion 2027-09
Phase Phase 2
Molecure S.A.

1 total trials

What NCT06205121 shows while recruiting

NCT06205121 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 796-participant average among 5 other Pulmonary Sarcoidosis trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Pulmonary Sarcoidosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06205121 names 20 study sites across 8 states, led by Other, Alabama, Kansas.

Frequently Asked Questions

What is clinical trial NCT06205121 about?

NCT06205121 is a clinical study titled "Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis". This is a Phase 2, randomized, double-blind, placebo-controlled, adaptive, multicenter study to evaluate the efficacy, safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of OATD-01 in the treatment of subjects with active pulmonary sarcoidosis.

What is the current status of trial NCT06205121?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2024-03-21. Estimated completion is 2027-09.

What conditions does trial NCT06205121 study?

This clinical trial studies the following conditions: Pulmonary Sarcoidosis.

What interventions are being tested in trial NCT06205121?

The interventions under investigation include: Placebo (DRUG), OATD-01 (DRUG).

Who is sponsoring clinical trial NCT06205121?

This trial is sponsored by Molecure S.A., which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06205121 being conducted?

This trial has 20 study locations across Alabama, Kansas, Maryland, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pulmonary Sarcoidosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03401762 · 96 participants · NA

    Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke

  • NCT03471260 · 96 participants · Phase 1

    Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • NCT03549559 · 96 participants · NA

    Imaging Histone Deacetylase in the Heart

  • NCT03841058 · 96 participants · Phase 2

    Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06205121, the US trial registry maintained by the National Library of Medicine. NCT06205121 (small enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.